On December 27, 2023, Ruibo (Hangzhou) Pharmaceutical Technology Co., Ltd. closed the transaction. The company has completed the industrial and commercial change registration and obtained a new Business License issued by the Hangzhou Qiantang District Market Supervision Administration.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.2 CNY | +0.28% |
|
-5.08% | -41.35% |
05-23 | Jiuzhou Pharmaceutical Plans CRO in Germany | MT |
05-14 | Ruibo Pharmaceutical Co., Ltd. announced that it has received CNY 300 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.35% | 1.76B | |
+51.63% | 796B | |
+40.84% | 628B | |
-5.10% | 358B | |
+19.90% | 331B | |
+9.95% | 301B | |
+17.49% | 244B | |
+3.93% | 228B | |
+12.76% | 214B | |
+6.99% | 165B |
- Stock Market
- Equities
- 603456 Stock
- News Zhejiang Jiuzhou Pharmaceutical Co., Ltd
- Ruibo Pharmaceutical Technology Co., Ltd. announced that it has received CNY 50 million in funding from Zhejiang Jiuzhou Pharmaceutical Co., Ltd